This makes little to no sense unless you take an absolutely literal view of the the "any price the market offers is in essence a fair market price" for the value of the engineers. You can't argue that without acknowledging that for the same reasons, until Apple offered those engineers more salary (and I don't think it was disclosed how different they were, just that someone made a comment of saying "$x is low"), then they were being paid the then-fair market value (I also think there's a
very cogent argument to be had that SF engineering compensation is inflated). But leaving that aside:
Masimo makes as you note, industrial devices. The Root devices that I mention are not ever going to be used at home, even by the ultra wealthy.
I mean you are talking about devices that do CO-oximetry (effectively "arterial blood gas"), brain function monitoring, connect to ventilators (ISA capnography for intubated patients) and anesthesia machines and pushing aggregated data into EPIC. Like I said, these are devices being used in intensive care units, not simple finger pulse oximetry, reflected or otherwise.
They are not "gatekeeping" this technology for the ultra wealthy so poor Apple Watch owners (of which I am on my third) can't get access to it. They're entirely different models with different purposes, in an entirely differing market segment.
Also if you're referring to "potentially life saving analysis" with respect to pulse oximetry on the Apple Watch, which does it only on demand, and is not an FDA regulated medical device, regardless of patents, there's an exaggeration happening. Patients with chronic hypoxic and similar issues are not relying on Apple Watches to "potentially save their lives".